drugset / Trial / NCT01520285

Compare the Effects of Lercanidipine Hydrochloride Tablet (Zanidip®) and Felodipine Sustained-Release Tablet for Hypertension

NCT01520285

Phase 4 Completed 281 enrolled Lee's Pharmaceutical Limited
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will be compare Felodipine sustained-release tablets, to Lercanidipine hydrochloride tablets (Zanidip®) for the treatment of patients with mild-to-moderate primary hypertension and to investigate the influence on patients' heart rate and blood pressure variability.

Timeline

Start
2011-12
Primary completion
2013-03
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Felodipine Small molecule 5 mg Oral
Comparator Lercanidipine Small molecule 10 mg Oral